A to Z / Growth hormone

Mod GRF (1-29)

Also known as CJC-1295 without DAC, modified GRF 1-29, sermorelin analogue.

Best known for Often confused with CJC-1295, and a different drug

Evidence★★☆☆☆

Safety dataPoorly characterised

Route Injectable (subcutaneous)

United StatesNot approved

AustraliaSchedule 4; captured by Appendix D cl.5 class entry (GHRHs)

as at 16 September 2026

What it is

Mod GRF (1-29) is sermorelin with four amino acid substitutions that resist enzymatic breakdown. Human data so far is limited to short pharmacokinetic work, and it is not approved. It is very commonly labelled “CJC-1295 no-DAC” or simply “CJC-1295”, and this naming overlap is the most consequential thing on this page.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with CJC-1295 (with DAC), Sermorelin, Ipamorelin, Tesamorelin

Related entries

CJC-1295 (with DAC)Half of the classic clinic growth hormone stack · Evidence ★★☆☆☆
SermorelinThe GHRH analogue once approved, now compounded · Evidence ★★★★☆
IpamorelinThe "clean" growth hormone secretagogue · Evidence ★★☆☆☆
TesamorelinThe only GHRH analogue with a current approval · Evidence ★★★★☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Mod GRF (1-29). It is not medical advice and not a recommendation to use it.